Ixekizumab and malignant neoplasms A pooled analysis of data from 25 randomized clinical trials
Merola et al. JAMA Dermatol 2025; 9:e252056
Merola et al. showed that the safety profile of ixekizumab (IXE) supports its long-term use in patients with PsO, PsA, or axSpA, without an increased risk for malignant neoplasm development. Merola et al. investigated the incidence rates of malignant neoplasms among patients with PsO, PsA, or axSpA who underwent long-term treatment with IXE, an IL- 17A antagonist.